Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MetaboGen
Gothenburg, Swedenmetabogen.se ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
MetaboGen has developed a proprietary platform integrating metagenomic analysis with strain identification to create next-generation probiotics. The company has conducted at least two clinical trials and holds several patents related to bacteriology, biotechnology, and combination drugs. As a wholly owned subsidiary of BioGaia AB since acquisition, it focuses on research and product development targeting the human microbiome for innovative probiotic products.
No detailed public results from specific clinical studies are available.- Therapeutic areas
- GastroenterologyOther
- Modalities
- Next-generation probioticsmicrobiome-based therapeutics
- Industry
- Biotech
02
Partnerships
Parent company BioGaia AB
Beyond the preview
Go deeper on MetaboGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetaboGen.